Cell free DNA analysis identifies actionable ERBB2 am plifications in patients with HER2 equivocal breast cancer

被引：0
|
作者：
Rich, T. A.
Raymond, V. M.
Ahn, E. R.
Banks, K. C.
Brufsky, A.
Lee, C.
Lippman, M.
Pluard, T. J.
Schwab, R. B.
Lanman, R. B.
机构：
[1] Guardant Hlth, Redwood City, CA USA
[2] Canc Treatment Ctr Amer, Chicago, IL USA
[3] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Pittsburgh, PA USA
[4] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[5] St Lukes Canc Inst, Kansas City, MO USA
[6] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P4-01-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-05
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cell free DNA analysis identifies actionable ERBB2 amplifications in patients with HER2 negative breast cancer
    Raymond, Victoria M.
    Diaz, Joseph
    Banks, Kimberly C.
    Ahn, Eugene
    Brufsky, Adam
    Ellis, Matthew
    Lippman, Marc
    Lee, Christine
    Pluard, Timothy
    Schreeder, Marshall
    Schwab, Richard
    Lanman, Richard B.
    CANCER RESEARCH, 2018, 78 (04)
  • [2] ERBB2 (HER2) Testing in Breast Cancer
    Hilal, Talal
    Romond, Edward H.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 315 (12): : 1280 - 1281
  • [3] Treatment options in ErbB2 (HER2)-overexpressing breast cancer
    Jackisch, Christian
    BREAST CARE, 2008, 3 : 1 - 1
  • [4] Challenges in the treatment of ErbB2 (HER2)-positiive breast cancer
    Jackisch, Christian
    EJC SUPPLEMENTS, 2008, 6 (05): : 7 - 14
  • [5] Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification
    Abdelhakeem, Ahmed
    Wang, Xuemei
    Rogers, Jane E.
    Trail, Allison
    Zhao, Meina
    Blum-Murphy, Mariela
    Estrella, J. S.
    Ajani, Jaffer A.
    ONCOLOGY, 2020, 98 (12) : 884 - 888
  • [6] Cell-free DNA (cfDNA) landscape in ERBB2 (HER2)-amplified Asian cancer patient population
    Lee, J.
    Franovic, A.
    Rich, T. A.
    Shiotsu, Y.
    Raymond, V. M.
    Lanman, R. B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Harari, D
    Yarden, Y
    ONCOGENE, 2000, 19 (53) : 6102 - 6114
  • [8] Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
    Daniel Harari
    Yosef Yarden
    Oncogene, 2000, 19 : 6102 - 6114
  • [9] Future options in the treatment of ErbB2 (HER2)-positive breast cancer
    Fumoleau, Pierre
    EJC SUPPLEMENTS, 2008, 6 (05): : 25 - 31
  • [10] Tucatinib HER2 (ErbB2) inhibitor Treatment of breast and colorectal cancer
    Patil, T.
    Shagisultanova, E.
    Borges, V. F.
    DRUGS OF THE FUTURE, 2019, 44 (01) : 11 - 19
12345